Background Sub-anaesthetic administration of ketamine is an emerging practice in patients
presenting treatment resistant depression (TRD), however several outstanding questions …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …

Ketamine is the prototype for a new generation of glutamate-based antidepressants that
rapidly alleviate depression within hours of treatment. Over the past decade, there has been …

BackgroundWhile oral antidepressants reach efficacy after weeks, single-dose intravenous
(iv) ketamine has rapid, yet time-limited antidepressant effects. We aimed to determine the …

Objective: Narrative review of the literature on the efficacy and safety of subanaesthetic
doses of ketamine for the treatment of depression. Method: Medline and PubMed databases …

Objectives. Suicidal behaviour (SB) entered the DSM-5, underlying a specific biological
vulnerability. Then, recent findings suggested a possible role of the immune system in SB …

Major depressive disorder (MDD) is a common psychiatric disorder with multifactorial
aetiology and complex pathophysiology. Despite availability of various pharmacological and …

The current systematic review and meta-analysis aimed at exploring acute effects of
intravenous (IV) ketamine, an antagonist of N-methyl-D-aspartate (NMDA), in subjects with …

Background: Severe depressive disorder is among most debilitating condition. Conventional
pharmacotherapy usually takes several weeks (usually 4–12 weeks) to improve symptoms …

Background A subanesthetic dose of ketamine provides rapid and effective antidepressant
effects, but the molecular mechanism remains elusive. It has been reported that …